About Scipher Medicine
Scipher Medicine is a company based in Waltham (United States) founded in 2014 by Joseph Loscalzo, Albert-Laszlo Barabasi, and Marcell Veidner. Scipher Medicine has raised $232.56 million across 9 funding rounds from investors including Khosla Ventures, TD Securities and Neuberger Berman. The company has 106 employees as of December 31, 2023. Scipher Medicine has completed 2 acquisitions, including CrossBridge and Yet2. Scipher Medicine offers products and services including Spectra AI Platform, Diagnostics, and Data Lake. Scipher Medicine operates in a competitive market with competitors including Guardant Health, GRAIL, Thrive Earlier Detection, Delfi Diagnostics and BillionToOne, among others.
- Headquarter Waltham, United States
- Employees 106 as on 31 Dec, 2023
- Founders Joseph Loscalzo, Albert-Laszlo Barabasi, Marcell Veidner
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Scipher Medicine
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$232.56 M (USD)
in 9 rounds
-
Latest Funding Round
$5.85 M (USD), Series D
May 02, 2024
-
Investors
Khosla Ventures
& 13 more
-
Employee Count
106
as on Dec 31, 2023
-
Investments & Acquisitions
CrossBridge
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Scipher Medicine
Scipher Medicine offers a comprehensive portfolio of products and services, including Spectra AI Platform, Diagnostics, and Data Lake.
Platform for analyzing patient data to optimize therapy selection.
Tools for biomarker-based therapy decisions in autoimmune diseases.
System for storing and analyzing clinical data for research insights.
People of Scipher Medicine
Unlock access to complete
Unlock access to complete
Funding Insights of Scipher Medicine
Scipher Medicine has successfully raised a total of $232.56M across 9 strategic funding rounds. The most recent funding activity was a Series D round of $5.85 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Scipher Medicine
Scipher Medicine has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Khosla Ventures, TD Securities and Neuberger Berman.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Secondary market fund focused on LP and direct secondary transactions
|
Locked | Locked | Locked | |
|
Venture capital funding is provided for technology and healthcare companies.
|
Locked | Locked | Locked | |
|
Venture capital investments in healthcare are focused on by aMoon.
|
Locked | Locked | Locked |
Investor details for Scipher Medicine
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Scipher Medicine
Scipher Medicine has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include CrossBridge and Yet2.
Investment portfolio details for Scipher Medicine
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Management consulting, technology scouting, and licensing services are provided.
|
Locked | Locked | 1999 | Locked | |
|
Chronic care planning and management software is provided.
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for Scipher Medicine
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Scipher Medicine
Detailed financials for Scipher Medicine
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Scipher Medicine Comparisons
Peer comparison for Scipher Medicine
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Scipher Medicine
Scipher Medicine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Thrive Earlier Detection, Delfi Diagnostics and BillionToOne, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
|
| Locked | Locked | Locked |
Provider of cell-free cancer liquid biopsy test
|
|
| Locked | Locked | Locked |
Liquid biopsy for post-cancer surgery tumor monitoring is provided.
|
Detailed competitors of Scipher Medicine
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Scipher Medicine
Complete news archive for Scipher Medicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scipher Medicine
Scipher Medicine was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Scipher Medicine is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Alif Saleh is the current CEO of Scipher Medicine.
Scipher Medicine is a funded company, having raised a total of $232.56M across 9 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Scipher Medicine is 106.
Scipher Medicine was founded in 2014 in Waltham, United States, within the biotechnology sector. Precision medicine services are offered through a platform that analyzes blood test reports to determine suitable drugs for patients. The PrismRA test is provided to predict responses to anti-TNF therapy prior to prescription. Focus is placed on autoimmune, neurological, and cardiovascular diseases, with operations centered on liquid biopsy technologies.
Scipher Medicine's top competitors include Guardant Health, GRAIL and BillionToOne.
Scipher Medicine offers Spectra AI Platform, Diagnostics, and Data Lake.
Scipher Medicine has made 2 acquisitions, including CrossBridge, and Yet2.
Scipher Medicine has 14 investors. Key investors include Khosla Ventures, TD Securities, Neuberger Berman, Monashee Investment Management, and Hitachi Ventures.